Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
NCT06932081
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Adult Congenital Heart Disease
- Congenital Heart Disease
- Systemic Right Ventricle
- Transposition of the Great Arteries
- Congenitally Corrected Transposition of the Great Arteries
- Fontan
- Single Ventricle
- Tetralogy of Fallot (TOF)
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Leiden University Medical Center
- Last updated on ClinicalTrials.gov
- February 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Johns Hopkins University · Baltimore, MD
Michigan · 1
- Helen DeVos Children's Hospital · Grand Rapids, MI
New York · 1
- Mount Sinai Fuster Heart Hospital · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.